

Kei Muro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5063719/publications.pdf>

Version: 2024-02-01

74
papers

13,543
citations

136885

32
h-index

85498

71
g-index

74
all docs

74
docs citations

74
times ranked

11917
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
2	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	6.3	1,749
3	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
4	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34.	1.0	1,187
5	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123
6	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
7	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	5.1	943
8	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	0.8	614
9	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239.	1.0	548
10	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3935-3943.	0.8	411
11	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	2.9	329
12	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 993-1001.	5.1	267
13	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1278-1286.	5.1	227
14	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>		
15	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
16	Comprehensive registry of esophageal cancer in Japan, 2012. <i>Esophagus</i> , 2019, 16, 221-245.	1.0	112
17	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5</i> colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	5.1	107
18	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1265-1272.	1.1	102

#	ARTICLE	IF	CITATIONS
19	A multicenter, open-label, single-arm study of anamorelin (ONO-67643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , 2019, 125, 4294-4302.	2.0	99
20	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
21	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 62-69.	0.6	70
22	The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018, 90, 63-72.	1.3	69
23	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 927-938.	2.7	67
24	Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. <i>BMC Palliative Care</i> , 2015, 14, 37.	0.8	63
25	Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer. <i>WJOG</i> 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850.	1.7	60
26	A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 321-326.	0.6	54
27	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017, 17, 132.	0.9	54
28	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	3.2	53
29	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	1.7	48
30	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. <i>Gastric Cancer</i> , 2019, 22, 817-827.	2.7	42
31	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2215-2222.	1.9	41
32	Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 913-920.	0.6	40
33	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 153-160.	1.2	26
34	Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). <i>Gastric Cancer</i> , 2020, 23, 677-688.	2.7	25
35	Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 214-223.	0.6	20
36	Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2974.	1.0	20

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1647.	1.0	18
38	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 237-247.	1.8	18
39	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	2.0	18
40	Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. <i>BMC Cancer</i> , 2019, 19, 652.	1.1	15
41	Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). <i>European Journal of Cancer</i> , 2020, 135, 11-21.	1.3	14
42	A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 601.	1.1	13
43	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
44	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 319-327.	1.0	11
45	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT). <i>TJ ETQq1 1 0.7843 14 rgBI1 Overlo</i>		
46	Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1229-1232.	0.6	10
47	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	1.6	9
48	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	1.0	8
49	Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. <i>Cancers</i> , 2020, 12, 844.	1.7	8
50	Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. <i>Esophagus</i> , 2022, 19, 137-145.	1.0	8
51	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPCCCT and WJOG6510G. <i>Cancers</i> , 2020, 12, 1715.	1.7	7
52	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	2.7	7
53	Chemotherapy for patients with advanced gastric cancer with performance status 2. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 220-4.	0.8	7
54	The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2015, 11, 1471-1478.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 575-582.	1.1	6
56	Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5433-5438.	0.5	6
57	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 595-603.	1.2	5
58	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1197-1203.	1.0	5
59	Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 355-363.	1.0	5
60	Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 508.	1.0	5
61	Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data. <i>Cancer Management and Research</i> , 2019, Volume 11, 2261-2267.	0.9	4
62	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
63	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. <i>Global Health & Medicine</i> , 2020, 2, 240-246.	0.6	4
64	Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 339-346.	0.6	3
65	Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). <i>BMC Cancer</i> , 2015, 15, 176.	1.1	2
66	Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?. <i>Lancet Oncology</i> , The, 2020, 21, 741-743.	5.1	2
67	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G. <i>Cancer Medicine</i> , 2021, 10, 7673-7682.	1.3	2
68	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, , .	1.3	2
69	Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2011, 47, 2673-2680.	1.3	1
70	An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study. <i>Future Oncology</i> , 2021, 17, 2431-2438.	1.1	1
71	Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. <i>Clinical Drug Investigation</i> , 2021, 41, 53-64.	1.1	1
72	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3686-3694.	3.2	1

#	ARTICLE	IF	CITATIONS
73	Phase I Study of Alternateâ€­Day Administration of Sâ€­1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1614-e1620.	1.9	0
74	<i>Society of Internal Medicine</i> , 2019, 108, 1777-1787.	0.0	0